Literature DB >> 10358137

Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development.

P V Sivakumar1, A Gunturi, M Salcedo, J D Schatzle, W C Lai, Z Kurepa, L Pitcher, M S Seaman, F A Lemonnier, M Bennett, J Forman, V Kumar.   

Abstract

Fetal liver- and thymus-derived NK1.1+ cells do not express known Ly-49 receptors. Despite the absence of Ly-49 inhibitory receptors, fetal and neonatal NK1.1+Ly-49- cells can distinguish between class Ihigh and class Ilow target cells, suggesting the existence of other class I-specific inhibitory receptors. We demonstrate that fetal NK1. 1+Ly-49- cell lysates contain CD94 protein and that a significant proportion of fetal NK cells are bound by Qa1b tetramers. Fetal and adult NK cells efficiently lyse lymphoblasts from Kb-/-Db-/- mice. Qa1b-specific peptides Qdm and HLA-CW4 leader peptide specifically inhibited the lysis of these blasts by adult and fetal NK cells. Qdm peptide also inhibited the lysis of Qa1b-transfected human 721.221 cells by fetal NK cells. Taken together, these results suggest that the CD94/NKG2A receptor complex is the major known inhibitory receptor for class I (Qa1b) molecules on developing fetal NK cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358137

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Reciprocal age related change in natural killer cell receptors for MHC class I.

Authors:  Charles T Lutz; Mikel B Moore; Sarah Bradley; Brent J Shelton; Susan K Lutgendorf
Journal:  Mech Ageing Dev       Date:  2005-02-19       Impact factor: 5.432

Review 2.  Extrinsic and intrinsic regulation of early natural killer cell development.

Authors:  Markus D Boos; Kevin Ramirez; Barbara L Kee
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Expression of the mouse MHC class Ib H2-T11 gene product, a paralog of H2-T23 (Qa-1) with shared peptide-binding specificity.

Authors:  Lili Chen; Eduardo Reyes-Vargas; Hu Dai; Hernando Escobar; Brant Rudd; Jared Fairbanks; Alexander Ho; Mathew F Cusick; Attila Kumánovics; Julio Delgado; Xiao He; Peter E Jensen
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

4.  Development of thymic NK cells from double negative 1 thymocyte precursors.

Authors:  Claudia L Vargas; Jennifer Poursine-Laurent; Liping Yang; Wayne M Yokoyama
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

5.  Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation.

Authors:  Russell E Vance; Amanda M Jamieson; Dragana Cado; David H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

6.  Chronic alcohol consumption enhances iNKT cell maturation and activation.

Authors:  Hui Zhang; Faya Zhang; Zhaohui Zhu; Dung Luong; Gary G Meadows
Journal:  Toxicol Appl Pharmacol       Date:  2014-12-09       Impact factor: 4.219

Review 7.  The role of CD94/NKG2 in innate and adaptive immunity.

Authors:  Anasuya Gunturi; Rance E Berg; James Forman
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Development and function of CD94-deficient natural killer cells.

Authors:  Mark T Orr; Jun Wu; Min Fang; Luis J Sigal; Pieter Spee; Thomas Egebjerg; Erik Dissen; Sigbjørn Fossum; Joseph H Phillips; Lewis L Lanier
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

9.  Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras.

Authors:  Emily T Durkin; Kelly A Jones; Deepika Rajesh; Aimen F Shaaban
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

10.  HLA reduces killer cell Ig-like receptor expression level and frequency in a humanized mouse model.

Authors:  Jeroen van Bergen; Allan Thompson; Melissa van Pel; Christelle Retière; Daniela Salvatori; David H Raulet; John Trowsdale; Frits Koning
Journal:  J Immunol       Date:  2013-02-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.